hotspot -WSS

hotspot

author：fashion 2025-10-04 11:50:18 - browse：99724

Primary care exam 01 — ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and Medtronic have run studies that showed renal denervation leads to a modest decrease in blood pressure. Adam Berry/Getty Images

The Food and Drug Administration approved a surgical system used to reduce blood pressure from Recor Medical, the company announced Wednesday. The treatment, called renal denervation, is controversial in the cardiology community due to its unclear efficacy.

Renal denervation is a treatment for patients who cannot manage standard doses of blood pressure medication — whether because the drugs aren’t effective enough for them, create overwhelming side effects, or become too cumbersome. The therapy, which is meant to be a one-time procedure, is administered via a catheter. Electrodes on the catheter then emit radiofrequency or ultrasound energy to block nerve signals from the kidneys that increase blood pressure.

The therapy, a simple procedure to reduce the blood pressure of millions of Americans, was once seen as a boon for cardiologists and device makers. But a large-scale clinical trial from Medtronic in 2014 called renal denervation’s efficacy into question, as it did not significantly reduce blood pressure compared to placebo treatments.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Why you shouldn’t ask, “What country has the best health care?”

leisure time

WSS

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

FTC sues over Novant Health acquisition of two N.C. hospitals

AMAs digital advisors table RPM coding reform proposal, again

Venture capital firm's plans to take over Akron hospital face hurdles

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

focus

hotspot

knowledge

Heart attack and stroke risk calculators need revising

Merck, Johnson & Johnson CEOs will testify on high drug prices

How one medical school became remarkably diverse

Zyn nicotine pouches become unlikely player in latest culture war

Guidelines to prevent youth baseball injuries need more muscle

Websites selling Wegovy, Zepbound ingredients targeted by FDA

DIEP, the 'gold standard' of breast reconstruction, is under threat

Having children helps parents live longer, especially after age 80

Peter Hotez and the public health issue of online harassment

Readout Newsletter: The latest on Novavax, Merck, Bluebird

leisure time

Bernie Sanders gets little from pharma CEOs on drug prices

ACIP vaccine advisory panel sees its vacancies filled

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Syphilis numbers in the United States reach record heights

Bernie Sanders gets little from pharma CEOs on drug prices

Merck, Johnson & Johnson CEOs will testify on high drug prices

explore

leisure time

focus

hotspot